Browse by Poster Title

• All
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z
• #

---

• F
• Favorite
  023

  FDA & EMA Regulatory Recommendations on Fed Bioequivalence Study in Healthy Subjects vs Patients for Generic Drug Development

  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET
  
• Favorite
  166

  Fetal & Neonatal Drug Exposure Following Nipocalimab Treatment in Pregnant Women at Risk of EOS-HDFN

  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET
• Favorite
  061

  First-in-Human Evaluation of Pharmacokinetics & Safety of Tilpisertib Fosmecarbil, an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor, in Healthy Volunteers

  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET
  
• Favorite
  076

  First-in-Human Phase 1 SAD, MAD, Food Effect & DDI Study of SGR-1505, a Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor, in Healthy Volunteers

  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET
• Favorite
  055

  First-in-Human Population PKPD Modelling & Simulation of CUE-101: Preliminary Results

  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET
  
• Favorite
  106

  First-in-Human Safety, Pharmacokinetics & Pharmacodynamics of the Oral Factor D Inhibitor BCX10013

  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET
  
• Favorite
  128

  Food & Formulation Effect of a Novel Src Homology Region 2 Domain−containing Protein Tyrosine Phosphatase 2 (SHP2) Allosteric Inhibitor in Combination With Pembrolizumab

  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET